New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report
ÌÇÐÄ´«Ã½
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION Carpenter, P. A., Kitko, C. L., Elad, S., Flowers, M. E., Gea-Banacloche, J. C., Halter, J. P., Hoodin, F., Johnston, L., Lawitschka, A., McDonald, G. B., Opipari, A. W., Savani, B. N., Schultz, K. R., Smith, S. R., Syrjala, K. L., Treister, N., Vogelsang, G. B., Williams, K. M., Pavletic, S. Z., Martin, P. J., Lee, S. J., Couriel, D. R. 2015; 21 (7): 1167-1187Abstract
The 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by the Ancillary Therapy and Supportive Care Working Group to support clinical ÌÇÐÄ´«Ã½ trials in chronic graft-versus-host disease (GVHD). Topics covered in that inaugural effort included the prevention and management of infections and common complications of chronic GVHD, as well as recommendations for patient education and appropriate follow-up. Given the new literature that has emerged during the past 8 years, we made further organ-specific refinements to these guidelines. Minimum frequencies are suggested for monitoring key parameters relevant to chronic GVHD during systemic immunosuppressive therapy and, thereafter, referral to existing late effects consensus guidelines is advised. Using the framework of the prior consensus, the 2014 NIH recommendations are organized by organ or other relevant systems and graded according to the strength and quality of supporting evidence.
View details for
View details for